[1] W.H.O. (WHO), Coronavirus Geneva WHO 2020 https://www.who.int/health-topics/coronavirus Access Date 21.1.2021, (2020).
[2] J.S. Peiris, K.Y. Yuen, A.D. Osterhaus, K. Stohr, The severe acute respiratory syndrome, The New England journal of medicine, 349 (2003) 2431-2441.
[3] https://www.worldometers.info/coronavirus/ (2021).
[4] https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.1, (2021).
[5] A. Casadevall, L.A. Pirofski, The convalescent sera option for containing COVID-19, The Journal of clinical investigation, 130 (2020) 1545-1548.
[6] H. DM., Emergency use authorization for COVID-19 convalescent plasma therapy. US Food and Drug Administration website. Published August 24, 2020. Accessed January 21, 2021. https://www.fda.gov/media/141477/download, (2020).
[7] G. Who Mers-Cov Research, State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans, PLoS currents, 5 (2013) ecurrents.outbreaks.0bf719e352e7478f7478ad7485fa30127ddb30128.
[8] I.F.N. Hung, K.K.W. To, C.K. Lee, K.L. Lee, W.W. Yan, K. Chan, W.M. Chan, C.W. Ngai, K.I. Law, F.L. Chow, R. Liu, K.Y. Lai, C.C.Y. Lau, S.H. Liu, K.H. Chan, C.K. Lin, K.Y. Yuen, Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection, Chest, 144 (2013) 464-473.
[9] L.J. Stockman, R. Bellamy, P. Garner, SARS: systematic review of treatment effects, PLoS medicine, 3 (2006) e343.
[10] I.F. Hung, K.K. To, C.K. Lee, K.L. Lee, K. Chan, W.W. Yan, R. Liu, C.L. Watt, W.M. Chan, K.Y. Lai, C.K. Koo, T. Buckley, F.L. Chow, K.K. Wong, H.S. Chan, C.K. Ching, B.S. Tang, C.C. Lau, I.W. Li, S.H. Liu, K.H. Chan, C.K. Lin, K.Y. Yuen, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 52 (2011) 447-456.
[11] T.C. Luke, E.M. Kilbane, J.L. Jackson, S.L. Hoffman, Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?, Annals of internal medicine, 145 (2006) 599-609.
[12] Y. Cheng, R. Wong, Y.O. Soo, W.S. Wong, C.K. Lee, M.H. Ng, P. Chan, K.C. Wong, C.B. Leung, G. Cheng, Use of convalescent plasma therapy in SARS patients in Hong Kong, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 24 (2005) 44-46.
[13] J.H. Ko, H. Seok, S.Y. Cho, Y.E. Ha, J.Y. Baek, S.H. Kim, Y.J. Kim, J.K. Park, C.R. Chung, E.S. Kang, D. Cho, M.A. Muller, C. Drosten, C.I. Kang, D.R. Chung, J.H. Song, K.R. Peck, Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience, Antiviral therapy, 23 (2018) 617-622.
[14] Y. Wang, P. Huo, R. Dai, X. Lv, S. Yuan, Y. Zhang, Y. Guo, R. Li, Q. Yu, K. Zhu, Convalescent plasma may be a possible treatment for COVID-19: A systematic review, International immunopharmacology, 91 (2021) 5.
[15] M.J. Joyner, J.W. Senefeld, S.A. Klassen, J.R. Mills, P.W. Johnson, E.S. Theel, C.C. Wiggins, K.A. Bruno, A.M. Klompas, E.R. Lesser, K.L. Kunze, M.A. Sexton, J.C. Diaz Soto, S.E. Baker, J.R.A. Shepherd, N. van Helmond, C.M. van Buskirk, J.L. Winters, J.R. Stubbs, R.F. Rea, D.O. Hodge, V. Herasevich, E.R. Whelan, A.J. Clayburn, K.F. Larson, J.G. Ripoll, K.J. Andersen, M.R. Buras, M.N.P. Vogt, J.J. Dennis, R.J. Regimbal, P.R. Bauer, J.E. Blair, N.S. Paneth, D. Fairweather, R.S. Wright, R.E. Carter, A. Casadevall, Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience, medRxiv : the preprint server for health sciences, (2020) 2020.2008.2012.20169359.
[16] M.J. Joyner, K.A. Bruno, S.A. Klassen, K.L. Kunze, P.W. Johnson, E.R. Lesser, C.C. Wiggins, J.W. Senefeld, A.M. Klompas, D.O. Hodge, J.R.A. Shepherd, R.F. Rea, E.R. Whelan, A.J. Clayburn, M.R. Spiegel, S.E. Baker, K.F. Larson, J.G. Ripoll, K.J. Andersen, M.R. Buras, M.N.P. Vogt, V. Herasevich, J.J. Dennis, R.J. Regimbal, P.R. Bauer, J.E. Blair, C.M. van Buskirk, J.L. Winters, J.R. Stubbs, N. van Helmond, B.P. Butterfield, M.A. Sexton, J.C. Diaz Soto, N.S. Paneth, N.C. Verdun, P. Marks, A. Casadevall, D. Fairweather, R.E. Carter, R.S. Wright, Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients, Mayo Clinic proceedings, 95 (2020) 1888-1897.
[17] A. Agarwal, A. Mukherjee, G. Kumar, P. Chatterjee, T. Bhatnagar, P. Malhotra, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ, 22 (2020).
[18] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial, Lancet, 397 (2021) 2049-2059.
[19] P.M. Manzini, G. Ciccone, F.G. De Rosa, R. Cavallo, V. Ghisetti, S. D'Antico, C. Galassi, F. Saccona, A. Castiglione, N. Birocco, T. Francisci, H. Hu, C. Pecoraro, F. Danielle, L. Labanca, A.M. Bordiga, M. Lorenzi, G. Camisasca, O. Giachino, M. Pagliarino, P. Ottone, I.T.D. Scuvera, R. Guaschino, R. Freilone, P. Berti, F. Pittaluga, M. Avolio, C. Costa, S. Raso, A. Nucci, M. Milan, A. Baffa, A. Russo, A. Tornello, L. Maddalena, G. Delios, F.P. Marletto, A.G. De Micheli, A. Mattei, S. Baldassano, F. Canta, M.L. Russo, D. Bergamo, F. Vitale, M.M. Liccardi, A. Chinaglia, A. Calcagno, M. Converso, C. Aldieri, V. Libanore, I. Blangetti, V. Benedetti, B. Mitola, G. Scozzari, Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial, BMC infectious diseases, 22 (2022) 879.
[20] K. Duan, B. Liu, C. Li, H. Zhang, T. Yu, J. Qu, M. Zhou, L. Chen, S. Meng, Y. Hu, C. Peng, M. Yuan, J. Huang, Z. Wang, J. Yu, X. Gao, D. Wang, X. Yu, L. Li, J. Zhang, X. Wu, B. Li, Y. Xu, W. Chen, Y. Peng, L. Lin, X. Liu, S. Huang, Z. Zhou, L. Zhang, Y. Wang, Z. Zhang, K. Deng, Z. Xia, Q. Gong, W. Zhang, X. Zheng, Y. Liu, H. Yang, D. Zhou, D. Yu, J. Hou, Z. Shi, S. Chen, Z. Chen, X. Zhang, X. Yang, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proceedings of the National Academy of Sciences of the United States of America, 117 (2020) 9490-9496.
[21] C. Shen, Z. Wang, F. Zhao, Y. Yang, J. Li, J. Yuan, F. Wang, D. Li, M. Yang, L. Xing, J. Wei, H. Xiao, J. Qu, L. Qing, L. Chen, Z. Xu, L. Peng, Y. Li, H. Zheng, F. Chen, K. Huang, Y. Jiang, D. Liu, Z. Zhang, Y. Liu, L. Liu, Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma, Jama, 323 (2020) 1582-1589.
[22] A.L. Zander, E.J. Olson, J.M. Van Gent, J. Bandle, R.Y. Calvo, S.R. Shackford, K.A. Peck, C.B. Sise, M.J. Sise, B.S. King, Does resuscitation with plasma increase the risk of venous thromboembolism?, The journal of trauma and acute care surgery, 78 (2015) 39-43.
[23] J.B. Holcomb, D.J. del Junco, E.E. Fox, C.E. Wade, M.J. Cohen, M.A. Schreiber, L.H. Alarcon, Y. Bai, K.J. Brasel, E.M. Bulger, B.A. Cotton, N. Matijevic, P. Muskat, J.G. Myers, H.A. Phelan, C.E. White, J. Zhang, M.H. Rahbar, The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks, JAMA Surg, 148 (2013) 127-136.
[24] N. Hadjesfandiari, E. Levin, K. Serrano, Q.-L. Yi, D.V. Devine, Risk analysis of transfusion of cryoprecipitate without consideration of ABO group, Transfusion, 61 (2021) 29-34.
[25] S.C. Meliga, W. Farrugia, P.A. Ramsland, R.J. Falconer, Cold-Induced Precipitation of a Monoclonal IgM: A Negative Activation Enthalpy Reaction, The Journal of Physical Chemistry B, 117 (2013) 490-494.
[26] C.R. Middaugh, B. Gerber-Jenson, A. Hurvitz, A. Paluszek, C. Scheffel, G.W. Litman, Physicochemical characterization of six monoclonal cryoimmunoglobulins: possible basis for cold-dependent insolubility, Proceedings of the National Academy of Sciences of the United States of America, 75 (1978) 3440-3444.
[27] C.D. Josephson, N.C. Mullis, C. Van Demark, C.D. Hillyer, Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy, Transfusion, 44 (2004) 805-808.
[28] J. Nie, Q. Li, J. Wu, C. Zhao, H. Hao, H. Liu, L. Zhang, L. Nie, H. Qin, M. Wang, Q. Lu, X. Li, Q. Sun, J. Liu, C. Fan, W. Huang, M. Xu, Y. Wang, Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay, Nature protocols, 15 (2020) 3699-3715.
[29] S.L. Emery, D.D. Erdman, M.D. Bowen, B.R. Newton, J.M. Winchell, R.F. Meyer, S. Tong, B.T. Cook, B.P. Holloway, K.A. McCaustland, P.A. Rota, B. Bankamp, L.E. Lowe, T.G. Ksiazek, W.J. Bellini, L.J. Anderson, Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus, Emerging infectious diseases, 10 (2004) 311-316.
[30] E. Salazar, P.A. Christensen, E.A. Graviss, D.T. Nguyen, B. Castillo, J. Chen, B.V. Lopez, T.N. Eagar, X. Yi, P. Zhao, J. Rogers, A. Shehabeldin, D. Joseph, C. Leveque, R.J. Olsen, D.W. Bernard, J. Gollihar, J.M. Musser, Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality, The American journal of pathology, 190 (2020) 2290-2303.
[31] S.T.H. Liu, H.-M. Lin, I. Baine, A. Wajnberg, J.P. Gumprecht, F. Rahman, D. Rodriguez, P. Tandon, A. Bassily-Marcus, J. Bander, C. Sanky, A. Dupper, A. Zheng, F.T. Nguyen, F. Amanat, D. Stadlbauer, D.R. Altman, B.K. Chen, F. Krammer, D.R. Mendu, A. Firpo-Betancourt, M.A. Levin, E. Bagiella, A. Casadevall, C. Cordon-Cardo, J.S. Jhang, S.A. Arinsburg, D.L. Reich, J.A. Aberg, N.M. Bouvier, Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study, Nature medicine, 26 (2020) 1708-1713.
[32] R. Libster, G. Pérez Marc, D. Wappner, S. Coviello, A. Bianchi, V. Braem, I. Esteban, M.T. Caballero, C. Wood, M. Berrueta, A. Rondan, G. Lescano, P. Cruz, Y. Ritou, V. Fernández Viña, D. Álvarez Paggi, S. Esperante, A. Ferreti, G. Ofman, Á. Ciganda, R. Rodriguez, J. Lantos, R. Valentini, N. Itcovici, A. Hintze, M.L. Oyarvide, C. Etchegaray, A. Neira, I. Name, J. Alfonso, R. López Castelo, G. Caruso, S. Rapelius, F. Alvez, F. Etchenique, F. Dimase, D. Alvarez, S.S. Aranda, C. Sánchez Yanotti, J. De Luca, S. Jares Baglivo, S. Laudanno, F. Nowogrodzki, R. Larrea, M. Silveyra, G. Leberzstein, A. Debonis, J. Molinos, M. González, E. Perez, N. Kreplak, S. Pastor Argüello, L. Gibbons, F. Althabe, E. Bergel, F.P. Polack, Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults, The New England journal of medicine, 384 (2021) 610-618.
[33] Y. Ventura-Enriquez, C. Cabello-Gutierrez, A.A. Perez-Calatayud, E. Cortina-De la Rosa, C.J. Fareli-Gonzalez, P. Castillo-Juarez, A.P. Carlos, E.O. Zavaleta-Martinez, E. Diaz-Padilla, S. Murrieta, V.D. Alvarez-Jimenez, J.A.D. Ponce-Medrano, C. Casillas-Suarez, M.A. Ocampo-Ocampo, C. Vargas-De-Leon, V. Fernandez-Sanchez, Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial, Life (Basel), 12 (2022).
[34] S. Korper, B. Gruner, D. Zickler, T. Wiesmann, P. Wuchter, R. Blasczyk, K. Zacharowski, P. Spieth, T. Tonn, P. Rosenberger, G. Paul, J. Pilch, J. Schwable, T. Bakchoul, T. Thiele, J. Knorlein, M.M. Dollinger, J. Krebs, M. Bentz, V.M. Corman, D. Kilalic, G. Schmidtke-Schrezenmeier, P.M. Lepper, L. Ernst, H. Wulf, A. Ulrich, M. Weiss, J.M. Kruse, T. Burkhardt, R. Muller, H. Kluter, M. Schmidt, B. Jahrsdorfer, R. Lotfi, M. Rojewski, T. Appl, B. Mayer, P. Schnecko, E. Seifried, H. Schrezenmeier, One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients, The Journal of clinical investigation, 132 (2022).
[35] V.A. Simonovich, L.D. Burgos Pratx, P. Scibona, M.V. Beruto, M.G. Vallone, C. Vázquez, N. Savoy, D.H. Giunta, L.G. Pérez, M.d.L. Sánchez, A.V. Gamarnik, D.S. Ojeda, D.M. Santoro, P.J. Camino, S. Antelo, K. Rainero, G.P. Vidiella, E.A. Miyazaki, W. Cornistein, O.A. Trabadelo, F.M. Ross, M. Spotti, G. Funtowicz, W.E. Scordo, M.H. Losso, I. Ferniot, P.E. Pardo, E. Rodriguez, P. Rucci, J. Pasquali, N.A. Fuentes, M. Esperatti, G.A. Speroni, E.C. Nannini, A. Matteaccio, H.G. Michelangelo, D. Follmann, H.C. Lane, W.H. Belloso, A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia, New England Journal of Medicine, 384 (2020) 619-629.
[36] E. Salazar, S.V. Kuchipudi, P.A. Christensen, T. Eagar, X. Yi, P. Zhao, Z. Jin, S.W. Long, R.J. Olsen, J. Chen, B. Castillo, C. Leveque, D. Towers, J. Lavinder, J. Gollihar, J. Cardona, G. Ippolito, R. Nissly, I. Bird, D. Greenawalt, R.M. Rossi, A. Gontu, S. Srinivasan, I. Poojary, I.M. Cattadori, P.J. Hudson, N.M. Josleyn, L. Prugar, K. Huie, A. Herbert, D.W. Bernard, J.M. Dye, V. Kapur, J.M. Musser, Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization, The Journal of clinical investigation, 130 (2020) 6728-6738.